1. Home
  2. ATXG vs APVO Comparison

ATXG vs APVO Comparison

Compare ATXG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addentax Group Corp.

ATXG

Addentax Group Corp.

SELL

Current Price

$2.39

Market Cap

4.5M

ML Signal

SELL

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$0.41

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATXG
APVO
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.3M
IPO Year
2015
2023

Fundamental Metrics

Financial Performance
Metric
ATXG
APVO
Price
$2.39
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $25.50
AVG Volume (30 Days)
31.9K
★ 129.1K
Earning Date
12-01-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.13
EPS
★ N/A
N/A
Revenue
N/A
★ $3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.38
52 Week High
$9.56
$10.70

Technical Indicators

Market Signals
Indicator
ATXG
APVO
Relative Strength Index (RSI) 37.69 9.01
Support Level $1.93 N/A
Resistance Level $3.97 $1.98
Average True Range (ATR) 0.36 0.10
MACD -0.00 -0.05
Stochastic Oscillator 33.80 3.22

Price Performance

Historical Comparison
ATXG
APVO

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services and Consulting. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: